Patents by Inventor Remi Guillon

Remi Guillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
    Publication number: 20220388979
    Abstract: The present invention relates to a compound suitable for use as a kinase inhibitor
    Type: Application
    Filed: August 7, 2020
    Publication date: December 8, 2022
    Applicant: B.C.I. PHARMA
    Inventors: Claire AMIABLE, Dominique SURLERAUX, François-Xavier DIEUDONNÉ, Thierry LOUAT, Sabrina DEROO, Rémi GUILLON
  • Adenine derivatives as protein kinase inhibitors
    Patent number: 11236093
    Abstract: The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3?, R4, R4?, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 1, 2022
    Assignee: B.C.I. Pharma
    Inventors: Dominique Surleraux, Claire Amiable, Rémi Guillon
  • Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents
    Patent number: 10626115
    Abstract: The present invention concerns novel fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their use as antifungal or antiparasitic agents.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITE DE NANTES
    Inventors: Cédric Loge, Rémi Guillon, David Montoir, Fabrice Pagniez, Patrice Le Pape
  • ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
    Publication number: 20190127379
    Abstract: The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3?, R4, R4?, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 2, 2019
    Applicant: B.C.I. PHARMA
    Inventors: Dominique Surleraux, Claire Amiable, Rémi Guillon
  • NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS
    Publication number: 20190002467
    Abstract: The present invention concerns novel fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their use as antifungal or antiparasitic agents.
    Type: Application
    Filed: July 22, 2016
    Publication date: January 3, 2019
    Applicant: UNIVERSITE DE NANTES
    Inventors: Cédric LOGE, Rémi GUILLON, David MONTOIR, Fabrice PAGNIEZ, Patrice LE PAPE
  • 5?-nucleotidase inhibitors and therapeutic uses thereof
    Patent number: 9783541
    Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: October 10, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, HOSPICES CIVILS DE LYON, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE DE MONTPELLIER 1
    Inventors: Laurent Chaloin, Suzanne Peyrottes, Corinne Lionne, Zsuzsanna Marton, David Egron, Remi Guillon, Christian Perigaud, Charles Dumontet, Lars Petter Jordheim, Isabelle Krimm
  • 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20160272643
    Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.
    Type: Application
    Filed: September 29, 2014
    Publication date: September 22, 2016
    Inventors: Laurent Chaloin, Suzanne Peyrottes, Corinne Lionne, Zsuzsanna Marton, David Egron, Remi Guillon, Christian Perigaud, Charles Dumontet, Lars Petter Jordheim, Isabelle Krimm